DALLAS, Aug. 28, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring ARIAD Pharmaceuticals Inc. (Nasdaq:ARIA). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on ARIAD Pharmaceuticals Inc. (Nasdaq:ARIA) should be of particular interest to pharmaceutical companies: Merck & Co. Inc. (NYSE:MRK), Eli Lilly & Co. (NYSE:LLY), Onyx Pharmaceuticals Inc. (Nasdaq:ONXX), Biogen Idec Inc. (Nasdaq:BIIB) and Amgen Inc. (Nasdaq:AMGN).
It is available at: http://www.investorsoup.com/lp/ARIA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
ARIAD Pharmaceuticals Inc. (ARIA) is a biopharmaceutical company that focuses on the discovery, development and commercialization of small-molecule drugs for the treatment of cancer. ARIA's portfolio of potential cancer drugs spans across a wide spectrum of major solid tumors such as breast and prostate cancers, as well as blood cancers such as chronic myelogenous leukemia (CML) and Acute myeloid leukemia (AML).
In the report, the analyst notes:
"On July 30, 2009, the Company reported that the progress of its late-stage SUCCEED trial, a test of oral ridaforolimus on patients with metastatic soft tissue and bone sarcomas, was on schedule. The Company expects to receive a first interim analysis of the treatment's efficacy from the independent Data Safety Monitoring Board (DSMB) in September 2009, and a second interim analysis from the DSMB by the end of the first quarter of 2010. The Company believes the second interim analysis will provide sufficient data on the treatment's efficacy and believes that a positive outcome would enable it to submit an application for FDA approval by mid-2010.
"ARIA's shares were up 5.2% on August 24, 2009, at $2.23 after the Company announced that the U.S. Court of Appeals for the Federal Circuit granted its petition for rehearing en banc and vacated its April decision in an appeal that Eli Lilly (NYSE:LLY) filed in 2008. The decision concerns a judgment holding LLY liable for infringement of U.S. Patent No. 6,410,516 (the '516 patent) licensed to ARIA by Harvard University, Massachusetts Institute of Technology and the Whitehead Institute for Biomedical Research."
To read the entire report visit: http://www.investorsoup.com/lp/ARIA
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.